Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in adults with persistent or chronic primary ITP
CTR20202482Phase 3Terminated
- Sponsor
- UCB
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rozanolixizumab in immune thrombocytopenia (ITP), sponsored by UCB. Started Dec 2020; status: terminated.
02
Drugs
rozanolixizumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20202482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202482.